title: Implication of sphingolipid metabolism in the stability of the Golgi apparatus.
abstract: We examined the effects of short chain and long chain ceramides on the stability of the Golgi apparatus. Short chain ceramides, C(2)- and C(6)-ceramides, blocked brefeldin A-induced Golgi disassembly without affecting the rapid release of Golgi coat proteins, whereas they did not inhibit brefeldin A-induced tubulation of endosomes. Both short chain ceramides also retarded Golgi disassembly induced by nordihydroguaiaretic acid and nocodazole, suggesting that they stabilize the Golgi apparatus. In contrast to short chain ceramides, natural long chain ceramides, when incorporated into cells or formed within cells upon treatment with sphingomyelinase or metabolic inhibitors, enhanced brefeldin A-induced Golgi disassembly. These results suggest that sphingolipid metabolism is implicated in the stability of the Golgi apparatus.
authors.affiliation: School of Life Science, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo 192-0392, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fukunaga
authors.forename: M
authors.initials: M
authors.lastname: Nagahama
authors.forename: K
authors.initials: K
authors.lastname: Hatsuzawa
authors.forename: K
authors.initials: K
authors.lastname: Tani
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Tagaya
mesh_terms: D000818:Animals; D020126:Brefeldin A / Q000494:pharmacology; D002417:Cattle; D002460:Cell Line; D002518:Ceramides / Q000378:metabolism* / Q000494:pharmacology; D020755:Coat Protein Complex I / Q000378:metabolism; D063388:Endocannabinoids; D011992:Endosomes / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology; D006056:Golgi Apparatus / Q000187:drug effects / Q000378:metabolism / Q000502:physiology* / Q000648:ultrastructure; D009637:Masoprocol / Q000494:pharmacology; D008854:Microscopy, Electron; D009025:Morpholines / Q000494:pharmacology; D015739:Nocodazole / Q000494:pharmacology; D009829:Oleic Acids; D013107:Sphingolipids / Q000096:biosynthesis / Q000378:metabolism*; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D021601:trans-Golgi Network / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure
chemical_list: D002518:Ceramides; D020755:Coat Protein Complex I; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D004983:Ethanolamines; D009025:Morpholines; C064769:N-acetylsphingosine; D009829:Oleic Acids; D013107:Sphingolipids; C101954:N-caproylsphingosine; C033595:N-oleoylethanolamine; D020126:Brefeldin A; C033110:RV 538; D009637:Masoprocol; D013108:Sphingomyelin Phosphodiesterase; D013110:Sphingosine; D015739:Nocodazole